Format

Send to

Choose Destination
Leuk Res. 2012 Dec;36(12):1475-80. doi: 10.1016/j.leukres.2012.08.006. Epub 2012 Aug 28.

Management of AML: who do we really cure?

Author information

1
Hematology/Oncology, JP Wilmot Cancer Center, University of Rochester Medical Center/Strong Memorial Hospital, Rochester, NY 14642, USA. jane_liesveld@urmc.rochester.edu

Abstract

Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at all stages of AML treatment if cure is to be realized in a higher proportion of patients. In order to improve outcome, requirements will include targeting the mutation responsible for the leukemia emergence, suppressing the stem or progenitor cell which acquires the mutation, and the capability to deliver therapy to patients who themselves have adverse co-morbidities.

PMID:
22938830
DOI:
10.1016/j.leukres.2012.08.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center